If you've been managing nerve pain for any length of time, you know the standard playbook by heart: gabapentin, pregabalin, duloxetine, an antidepressant or two, maybe a lidocaine patch, and eventually, “let's see if we can get you to tolerate it.” These drugs help some people. They don't help enough people. And not one of them was originally designed for nerve pain — they were all repurposed from other conditions after researchers noticed they happened to dull burning feet.
That's about to change. After more than two decades of false starts and Phase 2 disappointments, a class of drugs designed from the ground up around the actual biology of pain is finally reaching patients. The story centers on a single protein with an unglamorous name — Nav1.7 — and the gene that makes it, SCN9A. If you want to understand where neuropathy treatment is going over the next five years, this is the science to learn.
I'm going to keep this as plain-language as I can. By the end you'll understand what these channels do, why they became the most-pursued pain target in modern medicine, why the first wave of drugs failed, and what's now in your doctor's near future.
What Voltage-Gated Sodium Channels Actually Do
Every nerve in your body works on electricity. Not metaphorically — literally. When a sensory nerve in your foot detects a stubbed toe, it generates a tiny electrical pulse that travels up to your brain. That pulse is called an action potential, and it's created by sodium ions rushing into the nerve cell through specialized doorways in the cell membrane.
Every nerve in your body runs on tiny electrical pulses, and those pulses are created by sodium ions rushing through doorways called sodium channels. Nav1.7, Nav1.8, and Nav1.9 are the three channels that specifically control pain signaling. Blocking the right one at the right place quiets pain without dulling the rest of the nervous system.
Those doorways are called voltage-gated sodium channels. They sit closed at rest. When the cell membrane voltage shifts just enough, the channels snap open, sodium pours in, and the electrical pulse fires. It's like a row of dominoes — once the first channel opens, the next one opens, and the signal races up the nerve fiber.
Humans have nine subtypes of voltage-gated sodium channel, named Nav1.1 through Nav1.9. Each one is built by a different gene, expressed in different tissues, and tuned for different jobs:
- Nav1.1, 1.2, 1.3, 1.6 — central nervous system (brain and spinal cord)
- Nav1.4 — skeletal muscle
- Nav1.5 — heart muscle (this one is critical — knock it out and your heartbeat stops)
- Nav1.7, 1.8, 1.9 — peripheral pain-sensing neurons (the dorsal root ganglia, or DRG)
The pain-channel trio — Nav1.7, Nav1.8, and Nav1.9 — is what we care about. They sit on the cell bodies and nerve fibers of the neurons that carry pain, temperature, and itch signals from your skin and organs up to your spinal cord. They're the on-switch for how loudly your body says “ow.”
Why Nav1.7 Became the Holy Grail
Of the three pain channels, Nav1.7 is what scientists call the “threshold channel.” Here's what that means in practice. Pain neurons are always receiving small electrical inputs — most of them too small to fire a real action potential and send a signal up to your brain. Nav1.7 acts like an amplifier. It takes those small inputs, boosts them just past the threshold, and lets the bigger Nav1.8 channel take over and propagate the signal. Without Nav1.7, the small inputs fizzle and never become pain.
Researchers suspected this for years, but the proof came from two extraordinary groups of people.
The People Who Feel No Pain
In 2006, a team led by Geoffrey Woods at Cambridge published a paper in Nature about a 10-year-old boy in Pakistan who was a street performer. His act involved walking on burning coals and stabbing himself with knives. He felt nothing. He had never felt pain in his life. By age 14, he had died — jumping off a roof on a dare, unable to recognize the danger.
The 2006 Nature paper by Cox and colleagues identified three Pakistani children with biallelic SCN9A loss-of-function mutations. All three had complete absence of pain perception from birth. All three had completely normal touch, vibration, temperature, and cognitive function.
This was the proof that Nav1.7 controls pain — and pain only.
His genome had two broken copies of the SCN9A gene — the gene that makes the Nav1.7 protein. Three other children from related families in his region had the same mutation and the same condition. They were perfectly healthy in every other way. Normal intelligence. Normal movement. Normal senses of touch, vibration, and temperature. They just couldn't feel pain.
This condition, called congenital insensitivity to pain, was the smoking gun. Knocking out Nav1.7 in humans abolished pain without affecting anything else important. It was the proof drug companies had been waiting for.
The People Who Feel Everything
The opposite story was just as instructive. People with gain-of-function SCN9A mutations — where the channel opens too easily or stays open too long — develop devastating pain syndromes:
- Inherited erythromelalgia — burning red feet and hands triggered by mild warmth, severe enough that patients soak in ice water for hours.
- Paroxysmal extreme pain disorder — sudden episodes of rectal, eye, or jaw pain, often starting in infancy.
- Idiopathic small-fiber neuropathy — about 30 percent of cases where doctors can't find a cause turn out to carry SCN9A variants.
The logic was now bidirectional and ironclad. Turn Nav1.7 off, pain disappears. Turn it up, pain takes over your life. Find a drug that selectively dials Nav1.7 down, and you have the first true pain medicine.
Why It Took 20 Years
If the target was so obvious, why are we still waiting? The honest answer is that the nine sodium channel subtypes are 80 percent identical in their amino acid sequences. They're cousins. A drug that hits Nav1.7 has a strong tendency to also hit Nav1.5 in the heart — which causes arrhythmias — or Nav1.4 in skeletal muscle, which causes weakness, or Nav1.1 and Nav1.2 in the brain, which causes seizures.
The bar for a useful Nav1.7 drug was punishing. Selectivity needed to be roughly 1,000 times stronger for Nav1.7 than for cardiac Nav1.5, or the heart side effects would kill the program. Hitting that target while maintaining good oral absorption, good brain penetration where you wanted it, and acceptable manufacturing chemistry has defeated most of the major pharmaceutical companies.
Pfizer, Roche, Xenon, Convergence, Biogen, and others have all spent hundreds of millions chasing selective Nav1.7 blockers. Most ran into the same wall: in animals the drugs worked beautifully, but in human trials the pain relief was modest, the selectivity wasn't quite tight enough, or the side effects were unacceptable. The industry quietly calls this graveyard of dead candidates the “Nav1.7 problem.”
The Breakthrough Came From Nav1.8
While most companies were stuck on Nav1.7, a smaller team at Vertex Pharmaceuticals pivoted. They reasoned that Nav1.8 — Nav1.7's downstream partner — might be an easier target. Nav1.8 isn't expressed in the heart or brain at meaningful levels. It sits almost exclusively in peripheral pain neurons. The selectivity problem dissolved.
In January 2025, the FDA approved suzetrigine, marketed as Journavx, the first selective Nav1.8 blocker. It's currently approved for moderate-to-severe acute pain — think post-surgical pain, broken bones — but trials in diabetic peripheral neuropathy and other chronic nerve pain conditions are well underway. Suzetrigine is the first non-opioid pain drug designed from the ground up around pain biology rather than borrowed from another disease.
This matters even if Nav1.8 isn't ultimately the perfect target. Suzetrigine proved that selective sodium channel blockade can work in humans without unacceptable side effects. It cracked the door open that the field had been pushing against for decades.
The Pipeline Heading Toward Patients
Behind suzetrigine, the rest of the pipeline is now moving faster than at any point in this field's history. Several programs are worth knowing about:
| Drug | Target | Stage |
|---|---|---|
| Suzetrigine (Journavx) | Nav1.8 | FDA approved (acute pain) |
| VX-993 | Nav1.8 | Phase 2 (diabetic neuropathy) |
| Pilavapadin (LX9211) | AAK1 → Nav indirect | Phase 3 (diabetic neuropathy) |
| ST-503 | SCN9A gene silencing | Preclinical (small-fiber) |
| Nav1.7 antibodies (several) | Nav1.7 | Phase 1 |
VX-993 — Vertex's follow-on Nav1.8 blocker, currently in Phase 2 trials for diabetic peripheral neuropathy and lumbosacral radiculopathy. Oral pill, designed for chronic daily use. If it succeeds, this would be the first selective sodium channel drug specifically labeled for neuropathy.
Pilavapadin (LX9211) — Lexicon Pharmaceuticals' candidate. It works through an indirect mechanism — inhibiting an enzyme called AAK1 that regulates Nav channel trafficking — but the end result is reduced nociceptor firing. Currently in Phase 3 trials for diabetic peripheral neuropathy.
ST-503 — A gene therapy, not a pill. It uses engineered zinc-finger proteins to silence the SCN9A gene directly in dorsal root ganglion neurons, mimicking what nature does in the congenital insensitivity to pain patients. The target is small-fiber neuropathy. This would be a one-time treatment, not a daily medication. It's still preclinical, but it represents where the field is heading: don't block the channel, just turn down the gene.
Antibody approaches — Several biotech companies are developing monoclonal antibodies designed to selectively block Nav1.7 without the small-molecule selectivity problem. Antibodies don't cross cell membranes the way small molecules do, which solves some of the off-target issues by design.
None of these are guaranteed to succeed. The history of this field is littered with promising candidates that failed late-stage trials. But the pipeline is real, the science is sound, and the proof of concept is now in hand.
What This Means If You're Living With Neuropathy Today
I want to be honest with you, because false hope is its own kind of cruelty. Most of these drugs are still 2 to 5 years away from being available for the average neuropathy patient. Some will fail along the way. Even when they arrive, they'll be expensive, they'll have their own side effects, and they won't work for everyone.
- Am I a candidate for any ongoing neuropathic pain clinical trials at your institution?
- What does my EMG and nerve conduction documentation look like — is it complete enough for new-drug insurance approval?
- Have you seen suzetrigine work for neuropathic pain off-label?
- Should I get genetic testing for SCN9A variants if my neuropathy is idiopathic?
- Which academic centers near me have peripheral neuropathy trial programs?
But here's what I want you to take from this. The pain you're managing isn't a problem science has given up on. It's a problem science has been working on intensely for 20 years and is finally starting to crack. The drugs you're taking right now — the gabapentin, the duloxetine — are the last generation of “borrowed” pain medications. The next generation is being built around the actual biology of your nerves.
If you're seeing a neurologist or pain specialist, it's worth knowing the language. You can ask whether you'd be a candidate for any of the ongoing clinical trials. Most academic medical centers have neuropathic pain trial enrollment. The ClinicalTrials.gov database is searchable by condition and location. Being in a trial gets you access to next-generation treatment years before it's commercially available, often with closer monitoring than standard care offers.
The Bigger Story
Nav1.7 and its sibling sodium channels are the first molecular targets that pain medicine has had where the science is genuinely solid. For most of medical history, pain was treated by accident — opium, then aspirin, then drugs developed for seizures or depression that turned out to also dull nerves. None of them addressed why pain neurons fire in the first place.
Now we know. Nav1.7 amplifies the signal. Nav1.8 propagates it. Nav1.9 keeps the neuron primed. Block the right one at the right place, and you can quiet pain without dulling the rest of the nervous system. The first drug in this family is approved. The next ones are in trials. The gene-therapy approach is real. The opioid alternatives so many of us have been waiting for are finally being engineered, not stumbled upon.
I've been writing about neuropathy long enough to remember when the standard advice was essentially “learn to live with it.” We're not in that world anymore. The science finally caught up to the suffering. The drugs are coming.
Frequently Asked Questions
Is Nav1.7 the same as the sodium channel that lidocaine blocks?
Not quite. Lidocaine is a non-selective sodium channel blocker — it blocks essentially all subtypes equally, which is why it has to be applied locally as a patch or injection. If you took lidocaine systemically at doses high enough to relieve neuropathic pain everywhere, it would stop your heart. The new generation of drugs aims to selectively block only Nav1.7 or Nav1.8, which lets them work systemically without the cardiac risk.
If Nav1.7 is so important, why isn't there a Nav1.7 drug available yet?
Selectivity. The nine sodium channel subtypes are very similar to each other, so a drug that hits Nav1.7 tends to also hit the heart channel Nav1.5. Achieving 1,000-fold selectivity has defeated most of the candidates that have entered clinical trials. The Nav1.8 channel turned out to be an easier target because it doesn't have the cardiac safety problem, which is why suzetrigine reached approval first.
Can I take suzetrigine for my chronic neuropathy now?
Suzetrigine is currently approved only for moderate-to-severe acute pain — the kind you'd have after surgery or an injury. It is not yet approved for chronic nerve pain. Clinical trials for chronic neuropathic pain conditions are underway, but your insurance won't cover it for that use yet. Talk to your doctor about whether enrollment in an ongoing trial might fit your situation.
Will these new drugs replace gabapentin and duloxetine?
Eventually, probably yes, for many patients. But the rollout will be gradual. The new drugs will start as second- or third-line options, used after the cheaper generics have been tried. As real-world experience grows and prices come down, the field will shift. The transition will take years, not months.
What's the difference between the gene-therapy approach (ST-503) and the pill approaches?
Pills like suzetrigine and pilavapadin work for as long as you take them — stop the pill, the effect ends within hours. Gene therapy like ST-503 aims to silence the SCN9A gene in your pain neurons, potentially producing a long-lasting effect from a single treatment. The trade-off is that gene therapy is harder to reverse if you have side effects, and the technology is much earlier in development. Both approaches are being pursued in parallel.
Do these drugs work for the same kinds of pain as opioids?
They're designed to work better than opioids for nerve pain specifically, because they target the source of the pain signal rather than dulling the brain's perception of it. They won't have the addiction risk of opioids or the cognitive fog. But they also won't help with non-nerve pain — bone pain, muscle pain, inflammatory pain — the way opioids can. They are specialized tools for one specific category of pain.
What can I do today to be ready for these treatments?
Three things. First, make sure your neuropathy diagnosis is documented thoroughly — EMG and nerve conduction studies, autonomic testing if relevant, and an etiology workup. Insurance approval for new drugs will require a documented diagnosis. Second, optimize what's optimizable now — blood sugar control if you're diabetic, B12 levels, alcohol intake, exposure to nerve-damaging medications. Third, build a relationship with a neurologist or pain specialist at an academic medical center; they'll be the first to know when trials open and when new approvals happen.
How do I find out about clinical trials I might qualify for?
The federal database at ClinicalTrials.gov is the authoritative source. Search by your condition and zip code. Print the trial information and bring it to your next appointment — your doctor can help you assess fit and contact the trial coordinators. Many academic medical centers also have neuropathy or pain clinical-trial offices that maintain their own enrollment lists.
About the Author
